Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary

Gynecologic Oncology

Volumn 133, Issue 1, 2014, Pages 100-104

  Takeuchi, Satoshi ^a   Lucchini, Martin ^a   Schmeler, Kathleen M ^a   Coleman, Robert L ^a   Gershenson, David M ^a   Munsell, Mark F ^a   Macapinlac, Homer A ^a   Ramirez, Pedro T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Low grade ovarian carcinoma; Total lesion glycolysis

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GLYCOLYSIS; HUMAN; MIDDLE AGED; OVARIAN LOW GRADE SEROUS CARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PATIENT MONITORING; PET-CT SCANNER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; (18)F-FDG PET/CT; ADOLESCENT; AGED; CARCINOMA; LOW-GRADE OVARIAN CARCINOMA; METHODOLOGY; MULTIMODAL IMAGING; OVARY TUMOR; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; TOTAL LESION GLYCOLYSIS; TUMOR RECURRENCE; YOUNG ADULT;

(18)F-FDG PET/CT; LOW-GRADE OVARIAN CARCINOMA; TOTAL LESION GLYCOLYSIS;

ADOLESCENT; ADULT; AGED; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84897446731     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.02.008     Document Type: Article

References (21)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. K. Levanon, C. Crum, and R. Drapkin New insights into the pathogenesis of serous ovarian cancer and its clinical impact J Clin Oncol 26 2008 5284 5293
3. A. Malpica, M.T. Deavers, K. Lu, D.C. Bodurka, E.N. Atkinson, and D.M. Gershenson et al. Grading ovarian serous carcinoma using a two-tier system Am J Surg Pathol 28 2004 496 504
4. J.D. Seidman, I. Horkayne-Szakaly, J.A. Cosin, H.S. Ryu, M. Haiba, and C.R. Boice et al. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum Gynecol Oncol 103 2006 703 708
5. D.M. Gershenson, C.C. Sun, K.H. Lu, R.L. Coleman, A.K. Sood, and A. Malpica et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary Obstet Gynecol 108 2006 361 368
6. NCCN Clinical Practice Guidelines in Oncology Ovarian cancer version 1 http://www.nccn.org/professionals/physician-gls/pdf/ovarian.pdf 2013
7. K.M. Schmeler, C.C. Sun, D.C. Bodurka, M.T. Deavers, A. Malpica, and R.L. Coleman et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum Gynecol Oncol 108 2008 510 514
8. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials J Nucl Med 47 2006 1059 1066
9. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma J Nucl Med 50 2009 340 347
10. B.A.M.J. Williams, S.J. Mandrekar, S. Cha, and A.F. Furth Finding optimal cutpoints for continuous covariates with binary and time-to-event outcomes 2006 Mayo Clinic Department of Health Sciences Research Ed. Rochester
11. B.E. Hillner, B.A. Siegel, A.F. Shields, D. Liu, I.F. Gareen, and E. Hunt et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry J Nucl Med 49 2008 1928 1935
12. B.E. Hillner, B.A. Siegel, D. Liu, A.F. Shields, I.F. Gareen, and L. Hanna et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry J Clin Oncol 26 2008 2155 2161
13. T. Torizuka, S. Nobezawa, T. Kanno, M. Futatsubashi, E. Yoshikawa, and H. Okada et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-d-glucose Eur J Nucl Med Mol Imaging 29 2002 797 803
14. L. Prayer, C. Kainz, J. Kramer, R. Stiglbauer, H. Schurawitzki, and M. Baldt et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer J Comput Assist Tomogr 17 1993 626 632
15. P. Gu, L.L. Pan, S.Q. Wu, L. Sun, and G. Huang CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis Eur J Radiol 71 2009 164 174
16. L.J. Havrilesky, S.L. Kulasingam, D.B. Matchar, and E.R. Myers FDG-PET for management of cervical and ovarian cancer Gynecol Oncol 97 2005 183 191
17. Y.E. Erdi, H. Macapinlac, K.E. Rosenzweig, J.L. Humm, S.M. Larson, and A.K. Erdi et al. Use of PET to monitor the response of lung cancer to radiation treatment Eur J Nucl Med 27 2000 861 866
18. 18F-FDG PET in nonsurgical patients with non-small cell lung cancer Eur J Nucl Med Mol Imaging 39 2012 27 38
19. H.H. Chung, H.W. Kwon, K.W. Kang, N.H. Park, Y.S. Song, and J.K. Chung et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer Ann Surg Oncol 19 2012 1966 1972
20. U. Tateishi, C. Gamez, S. Dawood, H.W. Yeung, M. Cristofanilli, and H.A. Macapinlac Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT Radiology 247 2008 189 196
21. 90Y selective internal radiation therapy plus chemotherapy Eur J Nucl Med Mol Imaging 38 2011 1289 1295